AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.2930
+0.0378 (14.81%)
At close: Jul 31, 2026, 4:00 PM EDT
0.2878
-0.0052 (-1.77%)
Pre-market: Aug 3, 2026, 9:11 AM EDT
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
7.71M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 6.50M |
| Immuron | 4.99M |
| Traws Pharma | 2.73M |
| Can-Fite BioPharma | 405.00K |
| Aprea Therapeutics | 123.30K |
| Aspire Biopharma Holdings | 34.56K |
AEON News
- 4 days ago - Lake Street starts Aeon Biopharma at Buy on potential of Botox competitor - TheFly
- 4 days ago - Aeon Biopharma initiated with a Buy at Lake Street - TheFly
- 7 days ago - Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards - GlobeNewsWire
- 19 days ago - Aeon announces pricing of upsized $13.75M public offering - TheFly
- 20 days ago - AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding - GlobeNewsWire
- 25 days ago - AEON Biopharma Registration statement: Registration filing - Filings
- 26 days ago - AEON Biopharma Registration statement: Registration filing - Filings
- 2 months ago - AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - GlobeNewsWire